Pacira Pharmaceuticals (82P) Stock Statistics & Valuation Metrics

Pacira Pharmaceuticals has a market cap or net worth of CHF750.54M. The enterprise value is $1.16B.

Pacira Pharmaceuticals has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Pacira Pharmaceuticals’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 1.20%.

The current PE Ratio of Pacira Pharmaceuticals is 196.2. Pacira Pharmaceuticals’s PEG ratio is -1.51.

In the last 12 months, Pacira Pharmaceuticals had revenue of 726.41M and earned 7.03M in profits. Earnings per share was 0.16.

In the last 12 months, operating cash flow was 142.22M and capital expenditures -9.51M, giving a free cash flow of 132.71M billion.

Pacira Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Pacira Pharmaceuticals upcoming earnings date is Aug 4, 2026, Before Open (Confirmed).

Pacira Pharmaceuticals as a current ratio of 4.54, with Debt / Equity ratio of 62.88%

In the past 12 months, Pacira Pharmaceuticals has paid 9.84M in taxes.

Pacira Pharmaceuticals EV to EBITDA ratio is 11.83, with an EV/FCF ratio of 10.60.

Pacira Pharmaceuticals has CHF202.18M in cash and marketable securities with CHF411.18M in debt, giving a net cash position of -CHF209.00M billion.

Gross margin is 79.34%, with operating margin of 4.58%, and net profit margin of 0.97%.

The average price target for Pacira Pharmaceuticals is CHF23.95, which is 11.43% higher than the current price. The consensus rating is Moderate Buy